New hope for rare blood cancers: interferon trial launches
NCT ID NCT07468916
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests ropeginterferon alfa-2b, a long-acting immune protein, in 35 adults with rare blood cancers like CMML and MDS/MPN overlap syndromes. The drug aims to slow cancer cell growth by boosting the immune system. Researchers will check safety, best dose, and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ropeginterferon alfa-2b
- What this could lead to
- If successful, this could provide a new treatment option for rare blood cancers like CMML and MDS/MPN overlap syndromes, potentially slowing disease progression.
- What could go wrong
- This is an early phase 2 trial with only 35 participants, so results may not apply to everyone. Side effects from interferon therapy, such as flu-like symptoms or fatigue, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Three-Drug cocktail aims to tame transplant complications in blood cancer patients